Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients
Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients
复制标题
DOI：
10.1111/j.1468-1331.2006.01638.x
复制
发表时间：
2007-02-01
影响因子：
5.1
通讯作者：
Arroyo, R.
中科院分区：
文献类型：
--
作者：
Alvarez-Lafuente, R.;Garcia-Montojo, M.;Arroyo, R.
我们通过评估复发缓解型多发性硬化（RRMS）患者外周血单个核细胞（PBMC）和血清样本中JC病毒（JCV）DNA流行率和病毒载量以及mRNA流行率和病毒载量，分析了β-干扰素（β-IFN）治疗对JC病毒（JCV）活跃复制的影响。从PBMC和血清中提取的DNA，以及从PBMC中提取的mRNA在146例RRMS患者（73例用β-IFN治疗，73例未治疗的患者）和73名匹配的健康献血者中通过定量实时PCR分析JCV基因组的存在。我们发现在用β-IFN治疗的RRMS患者和未治疗的RRMS患者的PBMC样品中相同的DNA患病率：6.8%（5/73）。通过检测血清中DNA含量和PBMCs中mRNA含量分析两组病毒的活跃复制情况，均未发现阳性样本。关于这些阳性样本的病毒载量，我们没有发现治疗和未治疗的RRMS患者之间的任何统计学显著差异：分别为28.6 +/- 7.2和32.3 +/- 8.4拷贝/μ g DNA。这些结果使我们得出结论，β-IFN单药治疗对JCV的主动复制没有任何影响。
We analyzed the effect of beta-interferon (beta-IFN) treatment over the active replication of JC virus (JCV) through the evaluation of JCV DNA prevalence and viral load in peripheral blood mononuclear cells (PBMCs) and serum samples, and mRNA prevalence and viral load, in relapsing-remitting multiple sclerosis (RRMS) patients. DNA extracted from PBMCs and serum, and mRNA extracted from PBMCs were analyzed in 146 RRMS patients (73 treated with beta-IFN, and 73 untreated patients), and 73 matched healthy blood donors for the presence of JCV genomes by quantitative real-time PCR assay. We found the same DNA prevalence in PBMC samples in RRMS patients treated with beta-IFN and in untreated ones: 6.8% (5/73). When we analyzed the viral active replication in both groups through the analysis of DNA prevalence in serum samples and the mRNA extracted from PBMCs, we did not find any positive sample. Regarding the viral load of those positive samples, we did not find any statistical significant difference between treated and untreated RRMS patients: 28.6 +/- 7.2 and 32.3 +/- 8.4 copies/mu g of DNA, respectively. These results lead us to conclude that beta-IFN treatment in monotherapy has not any effect on JCV active replication.